PMID: 9650539Jul 3, 1998Paper

Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy

Journal of Clinical Pharmacology
G M LawsonN S Jiang

Abstract

As part of a clinical trial investigating the level of nicotine replacement with different doses of transdermal therapy for smoking cessation, peak and trough serum nicotine and plasma cotinine concentrations were measured in 70 subjects while they were actively smoking (baseline) and daily for 6 consecutive inpatient days while they were receiving transdermal nicotine. Subjects were randomly assigned to a daily 24-hour patch delivering a transdermal nicotine dose of 0, 11, 22, or 44 mg and stratified by self-reported smoking rate as either light (10-15 cigarettes per day), moderate (16-30 cigarettes per day), or heavy (>30 cigarettes per day). Steady-state concentrations of nicotine and cotinine were attained in 1 and 3 days, respectively, at all doses and were independent of baseline smoking rate. Mean percentage replacement of nicotine was calculated by dividing steady-state peak nicotine or cotinine concentrations by their respective baseline concentrations. Significant underreplacement occurred in subjects receiving the 11 mg/day patch regardless of baseline smoking rate. Underreplacement also occurred in moderate and heavy smokers receiving 22 mg/day and in light smokers at this same dose. Complete replacement occurred on...Continue Reading

References

Aug 1, 1991·The New England Journal of Medicine·P TønnesenU Säwe
Jan 1, 1990·Lung·P MüllerD Mauli
Mar 1, 1990·Clinical Pharmacology and Therapeutics·J E RoseC Schur
Mar 1, 1990·Clinical Pharmacology and Therapeutics·S C MulliganJ G Kelly
Jan 1, 1989·European Journal of Clinical Pharmacology·Y B BannonS Mulligan
Nov 17, 1988·The New England Journal of Medicine·N L Benowitz
Nov 1, 1995·JAMA : the Journal of the American Medical Association·D E JorenbyT B Baker
Nov 1, 1995·JAMA : the Journal of the American Medical Association·L C DaleD R Schroeder
Jul 1, 1993·Clinical Pharmacology and Therapeutics·R D HurtP J Hauri
Mar 1, 1993·Clinical Pharmacology and Therapeutics·N L Benowitz, P Jacob

❮ Previous
Next ❯

Citations

Nov 26, 2009·Psychopharmacology·Elysia SmallAdrie W Bruijnzeel
Jan 21, 2004·Addictive Behaviors·Jon O EbbertRichard D Hurt
Sep 16, 1999·American Journal of Obstetrics and Gynecology·P L OgburnT P Moyer
Mar 20, 2002·Pharmacology, Biochemistry, and Behavior·Mark G LeSagePaul R Pentel
Mar 21, 2002·Clinics in Chest Medicine·Richard D Hurt, Jon O Ebbert
Jun 28, 2006·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Paul M CinciripiniDavid W Wetter
Jan 5, 2002·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·R D Hurt
Jan 18, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Shayna T BradfordAnuska V Andjelkovic
Jul 12, 2013·PloS One·Zhifeng SunZhengguo Xiao
Aug 29, 2003·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Steven L Bramer, Beatrice A Kallungal
Sep 5, 2013·Mayo Clinic Proceedings·John E HodgkinJanet Brigham
Nov 17, 2009·Reproductive Biomedicine Online·Aldo CalogeroEnzo Vicari
Mar 21, 2006·Critical Care Nursing Clinics of North America·Robin L Corelli, Karen Suchanek Hudmon
Apr 20, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Felix HammannJuergen Drewe
Feb 15, 2015·Toxicology Letters·Daniel PollackMargarita Vigodner
Feb 16, 2007·Drug and Alcohol Dependence·Jon O EbbertRichard D Hurt
May 26, 2005·Anesthesiology·David O WarnerDarrell R Schroeder
Jan 9, 2010·Therapeutic Advances in Respiratory Disease·Karen Suchanek HudmonAlexander V Prokhorov
Apr 19, 2007·Molecular Reproduction and Development·Ying LiuThomas D Bunch
Dec 25, 2007·Molecular Reproduction and Development·Ying LiuThomas D Bunch
Oct 26, 2018·American Journal of Physiology. Lung Cellular and Molecular Physiology·Shama AhmadAftab Ahmad
Oct 28, 2003·Clinical Chemistry·Peter JatlowStephanie S O'Malley
Oct 31, 2000·Hospital Practice·J Meires, L Kuritzky

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.